Posted on: Tue 03-11-2026

A major breakthrough in the fight against malaria has emerged after Gavi, the Vaccine Alliance, and UNICEF secured a 40% reduction in the price of a leading malaria vaccine, a move expected to save around $50 million and expand access for children in countries hardest hit by the disease.

The price cut is being hailed as a significant step towards accelerating malaria prevention efforts across Africa, where the disease continues to claim hundreds of thousands of lives each year, most of them young children. By lowering procurement costs, governments and health partners will be able to purchase more vaccine doses with existing funding, helping to reach larger populations at risk.

Health officials say the savings generated through the new agreement could strengthen immunisation programmes and improve the sustainability of malaria vaccination campaigns. The reduced price is also expected to help countries introduce the vaccine more quickly and scale up distribution in communities where malaria remains a major public health threat.

Gavi and UNICEF described the agreement as an important milestone in making life-saving vaccines more affordable and accessible. The organisations noted that expanding access to malaria vaccines is a critical component of broader efforts to reduce malaria-related illness and deaths worldwide.

Public health experts believe the move could significantly boost global malaria-control strategies by allowing scarce health resources to stretch further while protecting more children from one of the world's deadliest infectious diseases.

The announcement comes as international health agencies continue to push for wider deployment of malaria vaccines, alongside existing prevention measures such as insecticide-treated bed nets, rapid testing, and effective treatment programmes. Together, these tools are expected to play a key role in reducing the burden of malaria in vulnerable regions.

---

---